Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Manuel Wiesinger"'
Autor:
Carola Berking, Gerold Schuler, Olaf Wolkenhauer, Annelies W Turksma, Heiko Bruns, Julio Vera, Martin Eberhardt, Manuel Wiesinger, Beatrice Schuler-Thurner, Cindy Flamann, Markus Vincent Heppt, Shailendra Gupta, Christopher Lischer, Johannes Berges, Esther Güse, Anja Wessely, Adrian Weich, Jimmy Retzlaff, Jan Dörrie, Niels Schaft, Johannes März, Harald Knorr, Krishna Pal Singh, Elias Andreas Thomas Koch, Nadine D van Kleef, Julian J Freen-van Heeren, Bettina Hohberger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline wou
Externí odkaz:
https://doaj.org/article/f5b73ac9110f43bf9d82c89934e31442
Autor:
Manuel Wiesinger, Diane Stoica, Susanne Roessner, Carmen Lorenz, Anika Fischer, Raja Atreya, Clemens F. Neufert, Imke Atreya, Alexander Scheffold, Beatrice Schuler-Thurner, Markus F. Neurath, Gerold Schuler, Caroline J. Voskens
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
In recent years, the exploration of regulatory T cell (Treg)-based cellular therapy has become an attractive strategy to ameliorate inflammation and autoimmunity in various clinical settings. The main obstacle to the clinical application of Treg in h
Externí odkaz:
https://doaj.org/article/f42462e4215c457a8d4a46b62ba624dd
Autor:
Manuel Wiesinger, Johannes März, Mirko Kummer, Gerold Schuler, Jan Dörrie, Beatrice Schuler-Thurner, Niels Schaft
Publikováno v:
Cancers, Vol 11, Iss 8, p 1198 (2019)
Chimeric antigen receptor (CAR)-T cells already showed impressive clinical regressions in leukemia and lymphoma. However, the development of CAR-T cells against solid tumors lags behind. Here we present the clinical-scale production of CAR-T cells fo
Externí odkaz:
https://doaj.org/article/4a6c4849d4dc4388a4da734f483068db
Autor:
Bianca Simon, Manuel Wiesinger, Johannes März, Kilian Wistuba-Hamprecht, Benjamin Weide, Beatrice Schuler-Thurner, Gerold Schuler, Jan Dörrie, Ugur Uslu
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 8, p 2365 (2018)
Natural killer T (NKT) cells represent a cell subpopulation that combines characteristics of natural killer (NK) cells and T cells. Through their endogenous T-cell receptors (TCRs), they reveal a pronounced intrinsic anti-tumor activity. Thus, a NKT
Externí odkaz:
https://doaj.org/article/41d8c8e0bb3840acaba709488aa477d0
Autor:
Tina Czerwinski, Lars Bischof, David Böhringer, Sibel Kara, Ernst Wittmann, Alexander Winterl, Richard Gerum, Gina Nusser, Manuel Wiesinger, Silvia Budday, Anja Lux, Caroline Voskens, Ben Fabry, Christoph Mark
To reach targets outside the bloodstream, immune cells can extravasate and migrate through connective tissue. However, in contrast to migrating mesenchymal cells, the importance of matrix adhesion and traction force generation for immune cell migrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b36fe7bca5a100e835200246c64bcd38
https://doi.org/10.1101/2023.04.20.537658
https://doi.org/10.1101/2023.04.20.537658
Autor:
Tanja M. Müller, Li-Juan Liu, Tina Czerwinski, Manuel Wiesinger, Mark Dedden, Eva-Maria Paap, Karen A.-M. Ullrich, Imke Atreya, Britta Siegmund, Raja Atreya, Ben Fabry, Carola Berking, Markus F. Neurath, Sebastian Zundler, Caroline J. Voskens
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology.
Autor:
Caroline Voskens, Diane Stoica, Marita Rosenberg, Francesco Vitali, Sebastian Zundler, Marion Ganslmayer, Heike Knott, Manuel Wiesinger, Jutta Wunder, Mirko Kummer, Britta Siegmund, Elisabeth Schnoy, Timo Rath, Arndt Hartmann, Holger Hackstein, Beatrice Schuler-Thurner, Carola Berking, Gerold Schuler, Raja Atreya, Markus F Neurath
ObjectiveUlcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an insufficient expansion of mucosal regulatory T cells (Tregs). We here re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50aee86c89ff90a5fd010dbd91715853
https://opus4.kobv.de/opus4-fau/files/21116/gutjnl-72-49.pdf
https://opus4.kobv.de/opus4-fau/files/21116/gutjnl-72-49.pdf
Publikováno v:
Cytotherapy. 21:1166-1178
Background Although dendritic cell (DC)–based cancer vaccines represent a promising treatment strategy, its exploration in the clinic is hampered due to the need for Good Manufacturing Practice (GMP) facilities and associated trained staff for the
Autor:
Caroline J Voskens, Diane Stoica, Susanne Roessner, Francesco Vitali, Sebastian Zundler, Marita Rosenberg, Manuel Wiesinger, Jutta Wunder, Britta Siegmund, Beatrice Schuler-Thurner, Gerold Schuler, Carola Berking, Raja Atreya, Markus F Neurath
Publikováno v:
BMJ Open
IntroductionAccumulating evidence suggests that the adoptive transfer of ex vivo expanded regulatory T cells (Treg) may overcome colitogenic immune responses in patients with inflammatory bowel diseases. The objective of the ER-TREG 01 trial is to as
Autor:
Manuel Wiesinger, Beatrice Schuler-Thurner, Tobias Altmann, Michael Erdmann, Mareke Brüning, Gerold Schuler, Ugur Uslu, Erwin Strasser
Publikováno v:
Journal of immunological methods. 463
Dendritic cell (DC)-based vaccines have been successfully used for immunotherapy of cancer and infections. A major obstacle is the need for high-level class A cleanroom cGMP facilities for DC generation. The CliniMACS Prodigy® (Prodigy) represents a